{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-296710","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2026-07-07T01:55:41+00:00","discovered_at":"2026-07-07T10:05:01.161380+00:00","generated_at":"2026-07-07T10:05:26.855536+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Vertex to acquire Crinetics Pharmaceuticals for $85.00 per share in cash; expected close Q3 2026","bullets":["Vertex to acquire Crinetics for $85.00 per share in cash; expected to close in Q3 2026.","$4.5B bridge loan facility from Bank of America and Morgan Stanley backs the deal; no financing condition.","Crinetics stockholders must approve; HSR and foreign regulatory clearances required; termination fee of $350M.","Vertex expects deal to accelerate revenue growth, with potential >$5B annual revenue; accretive to non-GAAP op income by 2029.","Crinetics' pipeline includes PALSONIFY (acromegaly) and atumelnant (CAH); Vertex sees significant commercial potential."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-296710","json":"https://secwatch.observer/filing/0001193125-26-296710.json","markdown":"https://secwatch.observer/filing/0001193125-26-296710.md","text":"https://secwatch.observer/filing/0001193125-26-296710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/0001193125-26-296710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/d113650d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T10:05:26.855536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}